TAVI: Transcatheter Tech. touts 30-day results of 'truly repositionable' valve
German device maker Transcatheter Technologies reports positive early findings from a study of its "game-changer" Trinity transcatheter aortic valve implantation system.
Emerging medical device maker Transcatheter Technologies GmbH unveiled an early look at clinical results for its 3rd-generation Trinity transcatheter aortic valve implantation platform, which the company calls "the world's 1st 'truly repositionable' and, therefore, best TAVI system."
The pilot results included 4 female patients, all of whom had no paravalvular leak at 30 days and no need for new pacemakers, the German company reported.